ASCO GUIDELINES Bundle

Immune-related Adverse Events CAR T-Cell Therapy

ASCO GUIDELINES App Bundle brought to you fcourtesy of Guideline Central. All of these titles are available for purchase on our website, GuidelineCentral.com. Enjoy!

Issue link: https://eguideline.guidelinecentral.com/i/1475467

Contents of this Issue

Navigation

Page 9 of 15

10 Management Table 2. ICANS Recommendations * Immune Effector Cell-Associated Encephalopathy (ICE) Assessment Tool: • Orientation: orientation to year, month, city, hospital: 4 points • Naming : ability to name 3 objects (e.g., point to clock, pen, button): 3 points • Following commands: ability to follow simple commands (e.g., "Show me 2 fingers" or "Close your eyes and stick out your tongue"): 1 point • Writing : ability to write a standard sentence (e.g., "Our national bird is the bald eagle"): 1 point • Attention: ability to count backwards from 100 by 10: 1 point ¥ For children age <12 years, the Cornell Assessment of Pediatric Delirium (CAPD) is recommended to aid in the overall grading of ICANS. A CAPD score of ≥9 is suggestive of delirium and should be considered Grade 3 ICANS. e CAPD score also may be used in patients age >12 years with baseline developmental delay as it has been validated up to age 21 years. ** For some products that may be associated with more neurotoxicity (axicabtagene ciloleucel or bexucabtagene autoleucel) earlier administration of steroids starting at G1 ICANS and use of high dose steroids at G3 may be an option. *** ICANS flares have been reported with rapid steroid taper. Close monitoring for ICANS relapse is encouraged during steroid taper. **** Noting limited experience with other agents, alternate options for persistent or worsening ICANS may include anakinra, siltuximab, ruxolitinib, cyclophosphamide, ATG, or intrathecal hydrocortisone (50 mg ) plus methotrexate (12 mg ). (cont'd)

Articles in this issue

Archives of this issue

view archives of ASCO GUIDELINES Bundle - Immune-related Adverse Events CAR T-Cell Therapy